Open AccessEvaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID‐19 in West Azerbaijan Province
Author(s) -
Gharebaghi Naser,
Farshid Saman,
Boroofeh Behdad,
Nejadrahim Rahim,
Mousavi Jalil,
Dindarian Sina,
Mohammadi Sedra
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14108
Subject(s) - medicine , epidemiology , logistic regression , diabetes mellitus , covid-19 , public health , pneumonia , pediatrics , disease , pathology , infectious disease (medical specialty) , endocrinology
Background COVID‐19 is considered a widespread concern in global public health. Diagnoses of COVID‐19 in some cases are necessary because of severe prognosis. In this study, epidemiologies, clinical and demographic characteristics of patients with COVID‐19 were studied in Taleghani Hospital, Urmia, Iran. Methods This descriptive‐analytical cross‐sectional study was carried out on 215 patients with COVID‐19 during March and April 2020. Approved COVID‐19 case was considered as a person with a positive respiratory sample performed by at least one of two RT‐PCR methods or genetic sequencing. ANOVA repeated measure, independent t‐test and logistic regression were done. A P < .05 was considered significant. Results The mean age of patients was 50.93 ± 17.92 years. Regarding gender, there were 91 females (42.3%) and 124 males (57.7%). The mean hospital stay, the temperature at admission, and onset of symptoms were 4.91 ± 3.68 days, 37.40 ± 0.96°C and 5.88 ± 4.80 days, respectively. Close contact with suspected people was found in 10.2% of patients. Additionally, 44 patients (20.5%) were smokers. Shortness of breath and cough were found in 62.8% and 49.3% of patients. Diabetes mellitus and hypertension were the most common comorbidities of patients. Regarding lung involvement, 33 patients (33%) were normal, most of the patients (n = 71) had 5%‐25% involvement in their lung and a minority of patients (n = 13) had a severe condition of 50%‐75% lung involvement. The association between smoking and mortality was tested using chi‐square showing no significant difference (X 2 :2.959, P = .085). There was no significant difference between AST, ALT, ALP, total, direct Bilirubin, lung involvement and suffering from fever ( P > .05). High Spo2 can increase the chance of recovery by 24% with each unit reduction. Kidney involvement increases the chance of death by about 80% (95% CI: 0.104‐0.013). The odds ratio of spo2 for recovery of COVID‐19 was 1.24 (95% CI: 1.014‐1.528; P = .037). Kaletra with odds ratio of 31.960 had the most highest effect on recovery following COVID‐19 ( P = .043). Conclusion COVID‐19 involves different organs of the body with different severity. In the meantime, smoking was not a risk factor for the virus or associated with severe manifestations of the disease. Patients with high creatinine and CPK, pulmonary involvement above 25%, and hypoxemia had a higher mortality rate. Increase of Spo2 by 1% can improve the patients by 24%. The results indicated that Kaletra had the most highest effect on improvement following COVID‐19.